Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial

Reuters2/23/2026

Summary

No summary yet.

Share:XRedditLinkedIn

Advertisement

Lindy Score Breakdown (V4.2)

48d
Age
2
Sources
from cluster
1168
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1168/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1168/48 = 0.000000) reduced it below 0.5

Story Timeline

  1. 2026-02-23
    Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial (current)

AnalysisRisk 20

Source Reputation: Moderate trust (10/20 pts)
Consensus: Emerging consensus: 2 sources
Age: 48 days - proven survivor

Same Story from 2 sources

Breaking Similar stories

Anti-Lindy Similar stories